Context Therapeutics News

Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected

US stocks look set to open higher in Thursday's trading session following the Federal Reserve's decision to leave rates unchanged Wednesday, and after jobless claims came in lower than expected earlie

MT NewswiresMay 2 21:23

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersAllarity Therapeutics (NASDAQ:ALLR) stock moved upwards by 106.6% to $2.83 during Thursday's pre-market session. The market value of their outstanding shares is at $5.5 million. Emergent BioSol

BenzingaMay 2 20:06

Context Therapeutics Secures Funding, Advances Clinical Trials

TipRanksMay 2 19:52

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers Company expects to enroll first patient in mid-2024 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics

GlobeNewswireMay 2 19:31

Context Therapeutics Announces $100 Million Private Placement

Financing includes new and existing leading healthcare investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 PHILADELPHIA, May 02, 2024 (GLOBE NEWSWIRE) --

GlobeNewswireMay 2 19:30

Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge

TipRanksApr 12 01:15

Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers

Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers

BenzingaApr 1 19:46

Context Therapeutics Advances Cancer Trial With FDA Submission

TipRanksApr 1 19:42

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio

GlobeNewswireApr 1 19:30

Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning

TipRanksMar 23 01:55

Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.

Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.

Dow JonesMar 22 00:31

Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 22 00:31

HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics with a Buy and lowers the price target from $5 to $4.

Analyst UpgradesMar 22 00:21

Preston Fay Brings Data Analytics Leadership to The Context Network

WEST DES MOINES, Iowa, March 21, 2024 /PRNewswire/ -- Agribusiness consulting firm The Context Network (Context) is growing its data analytics practice, with Preston Fay joining the leadership team a

PR NewswireMar 21 23:45

Context Therapeutics Reports FY Results

Seeking AlphaMar 21 22:44

Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M

Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M

BenzingaMar 21 19:49

Press Release: Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Context Therapeutics Reports Full Year 2023 Operating and Financial Results CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Compan

Dow JonesMar 21 19:43

Context Therapeutics Unveils Updated Corporate Strategy Presentation

TipRanksMar 6 20:42

12 Health Care Stocks Moving In Friday's After-Market Session

GainersAclarion (NASDAQ:ACON) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million. Outset Medical (NASDAQ:OM) shares rose 10.61% to $4.95. T

BenzingaJan 13 05:31

Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday

U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today's session. Battalion Oil Corporation (NYSE:BATL) rose 8

BenzingaDec 15, 2023 23:21